Drugs used for the treatment of pain Simple Analgesics Weak Opioids Strong Opioids Oral Strong Opioids Transdermal Strong Opioids Subcutaneous
|
|
- Milton Phillips
- 5 years ago
- Views:
Transcription
1 Drugs used for the treatment of Simple Analgesics Weak Opioids Strong Opioids Oral Strong Opioids Transdermal Strong Opioids Subcutaneous Adjuvant analgesics Non Steroidal Anti-Inflammatory Drugs (NSAIDs) Topical treatments Nutraceuticals Anti-migraine drugs acute attack Anti-migraine drugs prophylaxis Skeletal Muscle Relaxants and Drugs for Nocturnal Cramps Updated:
2 The current BNF contains a plethora of information with regards to the management of. Further information can also be found in the following guidelines: THPCT Persistent guidelines THPCT Palliative care guidelines WHO ladder The Long Term Neurological conditions National Service Framework outlines the commitment of the Department of Health to transform the way health and social care services support people living with long-term neurological conditions including persistent. For more information visit the Department of Health website: Dental and orofacial Analgesics should only be used in dental care as a temporary measure until the cause of has been rectified. Analgesics provide temporary relief and the choice should be based on the suitability of the patient. Most dental is relieved by paracetamol, ibuprofen or aspirin and an opioid (relatively ineffective in dental ) is rarely required. Prescription requirements for controlled drugs Prescriptions for Controlled Drugs that are subject to prescription requirements must be indelible, and must be signed by the prescriber, be dated, and specify the prescriber's address. The prescription must always state: Name and address of the patient In the case of a preparation, the form and where appropriate the strength of the preparation; Either the total quantity (in both words and figures) of the preparation, or the number (in both words and figures) of dosage units, as appropriate, to be supplied; in any other case Total quantity (in both words and figures) of the Controlled Drug to be supplied Dose (and the words for dental treatment only' if issued by a dentist) Prescriptions for Controlled Drugs in Schedules 2, 3, and 4 should usually be limited to a supply of up to 30 days treatment. Further information is available at Back Simple Analgesics
3 Paracetamol Mild to Moderate, soluble tablets, suspension, suppositories The effect of regular paracetamol (i.e. 1g 4 times a day) is greater than taking paracetamol on a PRN basis. Max daily dose of paracetamol is 4g/daily. Sugar free (SF) suspensions need to be requested. Care when prescribing soluble tablets sodium content of soluble tablets is 18mmol/tablet, this equates to 0.43g/tablet. A full daily dose (8 tablets) equates to 3.44g per day of sodium. Weak Opioids Codeine Mild to, moderate linctus Dihydrocodeine Moderate to severe, oral solution Max dose 240mg/day in divided doses long term use not advisable due to constipation. Max dose 240mg/day in divided doses higher doses cause more nausea & vomiting. Max dose 400mg/day. Not as effective in severe as other opioids. Tramadol Moderate to severe Capsules, dispersible tablets Care when prescribing with antidepressants several cases of serotonin syndrome reported. Caution should be exercised even though evidence of actual risk is small. Care when prescribing in the elderly as confusion and sedation are common with tramadol there is a high risk of falls. MR versions of tramadol are not recommended as there is no evidence of increased efficacy over normal release capsules. Compound analgesics, preparations that contain a simple analgesic such as paracetamol with an opioid component, reduce the scope for effective titration of the individual components in the management of of varying intensity.
4 Drug compound Indication Formulation Notes on prescribing The strength of co-codamol required (i.e. 8/500 or 30/500) should always be specified on prescriptions. Co-codamol (paracetamol + codeine) Co-dydramol (paracetamol + dihydrocodeine) Mild to moderate Moderate to severe, soluble tablets Note: For the co-codamol 30/500 preparation prescribing should be restricted to short term use only after a surgical procedure or accident as the codeine content at the maximum dose is high. Care when prescribing soluble tablets sodium content of soluble tablets is between mmol/tablet, depending on the brand. A full daily dose (8 tablets) equates to between g per day of sodium. The strength of co-dydramol required (i.e. 10/500 or 30/500) should always be specified on prescriptions. TNDG: Combined products of tramadol and paracetamol are NOT recommended as they do not contain effective doses of either analgesic. Back Strong Opioids Oral Morphine sulphate Severe Normal release tablets,oral solution MR tablets MR capsules MR sachets MXL capsules are a once a day preparation other preparations of morphine are 12 hourly. Please ensure the correct preparation and dose and frequency are prescribed. MXL and Zomorph capsules can be swallowed whole, opened and put in semisolid food or given via PEG tube.
5 Oxycodone and naloxone [Targinact] Oxycodone hydrochloride Severe and constipation Severe Film coated MR tablets Normal Release Capsules,oral solution MR TNDG: Targinact is not recommended for routine analgesic use. Targinact is recommended for patients unable to achieve adequate analgesia on an optimal opiate dose of morphine (1st line) and oxycodone (2 nd line) due to intolerable GI side effects which can not be alleviated by optimal laxatives and antiemetics. All patient selection to be undertaken by a Pain Consultant BLT to initiate and prescribe for the first month. Patients to be reviewed for analgesia and GI side-effects after 4-8 weeks after initiation. Targinact to be stopped if no significant improvement of analgesia/side effects is achieved. GPs could continue to prescribe maintenance Targinact and monitor patients. If the Pain Team proposes to expand these criteria for use, a case should come back to the Trust New Drugs Group Click here for algorithm for initiation and discontinuation advice TNDG: For those in whom morphine is either not effective enough or side effects are not tolerable - changing to a different opioid may result in a lessening or elimination of the side effect and/or improved analgesia. Multiple medication errors have been reported with oxycodone preparations. It is essential that the correct formulation is prescribed and its use explained to the patient. OxyNorm is NORMal release preparation OxytContin is a CONTINuous (MR) preparation The starting dose of opioid depends on previous analgesia use, age and medical condition. Immediate release preparations have a rapid onset and short duration of action, allowing steady state to be achieved quickly. It is important to review the daily dose of opioid regularly. 12 hourly modified release preparations (MR) are intended for maintenance when the dose is stable. These are NOT suitable for acute relief because of its slow onset. Patients on MR preparations must also be written up for treatment of breakthrough. Prescribe MR preparations by both brand and approved name to avoid confusion. To convert to 12 hourly MR preparations from immediate release:
6 Total oral morphine dose over previous 24 hours 2 = 12 hourly MR Morphine every 12 hours To calculate breakthrough Total oral MR morphine dose over 24 hours 6 = breakthrough dose that can be taken 4 hourly (normal release only) Strong Opioids Oromucosal Fentanyl Back Severe breakthrough Strong Opioids Transdermal Lozenge (with oromucosal applicator) TNDG: Fentanyl lozenges should be initiated at the recommendation of a Palliative Care Specialist. Approved for patients with chronic stabilised on a strong opioid and meeting one or more of the following criteria: Breakthrough of short duration and who have intolerable adverse effects from their normal release opioid and where dextromoramide is not appropriate/or effective. The onset of action of oral preparations is too slow requiring parenteral analgesia to be administered. Patient has severe dysphagia and is unable to swallow (e.g. oesophageal cancer) and where there is no alternative access such as a PEG tube, or where absorption from the oral route is incomplete (e.g. short bowel syndrome).
7 Fentanyl Buprenorphine 96 hour patches Buprenorphine 7 day patches Severe Severe Severe 72 hour transdermal patches [Transtec ] 96 hour transdermal patches [Butrans ] 7 day transdermal patches TNDG: For those who cannot swallow tablets and for those in whom morphine is either not effective or side effects are intolerable - changing to a different opioid may result in a lessening or elimination of the side effect and/or improved analgesia. Administration: Avoid using the same area for several days. These should be prescribed by brand name as different brands are not necessarily equivalent. Administration: Avoid using the same area for at least 6 days. These should be prescribed by brand name as different brands are not necessarily equivalent. These are second line patches and should be prescribed upon recommendation from the clinic or by experienced clinicians only. Administration: Avoid using the same area for at least 3 weeks These should be prescribed by brand name as different brands are not necessarily equivalent. Patches: Administration: Apply to dry, non-irritated, non-irradiated, non-hairy skin on torso or upper arm. The replacement patch should be sited on a different area. Fever or external heat may cause increased absorption; monitor for increased side-effects. Buprenorphine and fentanyl are drugs with very long duration of action. For advice on dose titration see current BNF. Side effects may persist for over 24 hours after patch removal. Strong Opioids Subcutaneous For information on controlled drugs and drug dependence and prescribing in palliative care please refer to the Guidance on Prescribing section in the current BNF.
8 Diamorphine Severe Injection, powder for reconstitution Morphine Severe Injection / infusion, Not suitable for oedematous patients. solution Oxycodone Severe Injection / infusion, solution The Scottish Medicines Consortium has advised (October 2004) that OxyNorm injection is used only in patients with cancer who have difficulty in tolerating morphine or diamorphine. Back Adjuvant analgesics
9 Unlicensed but Amitriptyline has established efficacy in neuropathic, migraine Oral solution prophylaxis According to local expert opinion (BLT Pain Clinic) max dose for neuropathic recommended is 50mg at night. The dose could be increased as tolerated up to the BNF maximum of 200mg per day to treat depression. It is especially important to exercise caution when using such doses in combination with serotonergic drugs like SSRIs and tramadol as there is a greater risk of serotonin syndrome. Trigeminal neuralgia max dose up to 1.6 g daily in some patients. Dose-related sideeffects of carbamazepine may be reduced by using the modified-release formulation. CSM: See current BNF for symptoms of blood, hepatic or skin effects that the patient needs to be aware of and report. Carbamazepine Trigeminal neuralgia only Normal release tablets Oral Solution Suppositories MR tablets Carbamazepine is a potent CYP450 enzyme inducer, as well as an auto inducer care should be exercised when prescribing concomitantly with other drugs especially those with narrow therapeutic indices (e.g. theophylline). The risk of hyponatraemia may be increased when prescribing with other drugs that deplete sodium (e.g. diuretics). TDM: Levels only required if toxicity or non-concordance is suspected. Target serum concentration: 4-12 mg / L Sample time: Trough i.e. pre-dose Notes: Time to steady state is 2-4 weeks while therapy is initiated, 4 days with chronic therapy. If levels are outside the therapeutic range, please assess patient concordance and contact the specialist for advice. Gabapentin Neuropathic Pain when amitriptyline is inappropriate Capsules M/R preparations Different preparations may vary in bioavailability; to avoid reduced effect or excessive side effects, it may be prudent to avoid changing the formulation. (The use of M/R tablets significantly lessens the incidence of dose-related side effects). Should be increased to maximum tolerated dose. Dose should be titrated according to BNF Patient should be warned about drowsiness and blurred vision which is usually transient. are very expensive
10 Nortriptyline Pregabalin [Lyrica ] (unlicensed in trigeminal neuralgia) Neuropathic (unlicensed) Neuropathic Capsules Maximum licensed dose for neuropathic is 3.6g/day. Initially 10-25mg Usual max dose = 75 mg daily; higher doses under specialist supervision only. Care when prescribing with antidepressants several cases of serotonin syndrome reported. Caution should be exercised even though evidence of actual risk is small. Useful for patients intolerant to the side effects of amitriptyline. TNDG: Approved for initiation by the specialist team and continuation by GPs. Non Steroidal Anti-Inflammatory Drugs (NSAIDs) CSM: NSAIDs may be associated with an increased risk of thrombotic events particularly when used at high doses for long term treatment. NSAIDs are associated with serious gastro-intestinal (GI) toxicity with a higher risk in the elderly. All non-selective NSAIDs are contraindicated in patients with a history of peptic ulceration. NSAIDs are contraindicated in heart failure. Combination of an NSAID and low dose aspirin or anti-coagulant can increase the risk of GI bleeding. Worsening of asthma or hypersensitivity reactions may be due to treatment with NSAIDs. The risk of bleeding is increased by the concurrent use of SSRIs and NSAIDs.
11 Ibuprofen Diclofenac Naproxen Mefenamic acid Selective COXII inhibitors Back Topical treatments Mild to moderate ; and inflammation in rheumatic disease and other musculoskeletal disorders; postoperative analgesia; migraine Pain and inflammation in rheumatic disease and other musculoskeletal disorders Pain and inflammation in rheumatic disease and other musculoskeletal disorders; dysmenorrhoea; acute gout Mild to moderate in rheumatoid and osteoarthritis;dysmenorrhoea and menorrhagia Pain and inflammation in osteo and rheumatoid arthritis Oral suspension EC tablets MR tablets suppositories EC tablets, capsules, paediatric oral suspension Ibuprofen is the traditional NSAID associated with the lowest level of gastro-intestinal risk. Increased thrombotic risk is very unlikely for shortterm low dose treatment. At high doses (>1200mg) there is an increased risk. Ibuprofen may reduce the cardioprotective effect of low-dose aspirin in people with cardiovascular disease. Studies looking at concomitant use of various NSAIDs with aspirin suggest that the risk of an interaction between ibuprofen and aspirin may be more likely when ibuprofen is taken regularly. MHRA: Diclofenac (particularly 150mg daily) may have a thrombotic risk similar to that of etoricoxib and possibly other coxibs. MHRA: Naproxen is associated with a lower thrombotic risk than coxibs, and epidemiological data do not suggest an increased risk of MI, however, some risk can not be excluded. It has occasionally been associated with diarrhoea and haemolytic anaemia which require discontinuation of treatment. Initiation by specialist advice recommended.
12 Drug Indication Formulation How prescribed Diclofenac Osteoarthritis Gel 1.16% Topical non-steroidal anti inflammatory drugs are considered to be of limited clinical value, hence generally deemed unsuitable for prescribing, however their use can be justified in certain circumstances: Short term use (<2 weeks) for acute musculoskeletal Treatment for osteoarthritis of the knee and hand for up to 12 weeks Based on the available evidence from clinical trials (NICE), for the treatment of osteoarthritis, topical NSAIDs could be prescribed for a maximum of 12 weeks after which treatment should be reviewed on a monthly basis. Lidocaine Post herpetic neuralgia Topical 5% plaster The patches are associated with a high frequency of adverse reactions, particularly dermatological. Each patch must be worn for only 12 hours per day and a maximum of three patches can be applied at any time. The plasters can be cut. TNDG: Approved for post herpetic neuralgia only. Post herpetic neuralgia. Transient burning sensation may occur during initial treatment, Capsaicin Cream 0.075% particularly if too much cream is used, or if the frequency of Painful diabetic neuropathy administration is less than 3 times daily, or if applied after a hot under supervision of hospital bath/shower. consultant Nutraceuticals Glucosamine sulphate Glucosamine hydrochloride Glucosamine + NICE: The use of other glucosamine and / or chondroitin products is not recommended for the treatment of osteo-arthritis.
13 chondroitin Anti-migraine drugs acute attack Initial treatment of migraine should be with simple analgesics like paracetamol and aspirin or an NSAID (preferably soluble formulation) with an anti-emetic if required. A 5HT agonist (triptans) should only be used if initial treatment has been tried and failed. Excessive use of treatments may be associated with Medication Overuse Headache (MOH) For acute migraine, triptans should only be used as monotherapy. Paracetamol Aspirin Sumatriptan Zolmitriptan Back See above dispersible preparations preferred. Treatment of acute migraine Treatment of acute migraine Treatment of acute migraine Dispersible tablets, tablets, nasal spray, injection Orodispersible tablets To be taken with or after food contraindicated in patients with active peptic/duodenal ulcers. Max Dose = 4g/day Nasal spray and s/c injection are very expensive. Discontinue if any tingling, heat heaviness, pressure or tightness of any part of the body becomes intense. CSM: Avoid in patients with ischaemic heart disease or Prinzmetal s angina as there have been reports of chest and tightness (coronary vasoconstriction). Orodispersible tablets are useful for those unable to swallow sumatriptan tablets due to vomiting. Discontinue if any tingling, heat heaviness, pressure or tightness of any part of the body becomes intense. Anti-migraine drugs prophylaxis When migraine attacks are frequent possible provoking factors such as stress, irregular lifestyles, chemical triggers (e.g. alcohol, cheese, caffeine chocolates and combined oral contraceptives) should be sought.
14 Pizotifen Propranolol Amitriptyline Topiramate Sodium valproate Migraine prophylaxis Migraine prophylaxis Commence low dose and titrate as necessary to reduce drowsiness. Can cause weight gain. CSM: beta blockers should not be given to people with a history of asthma or bronchospasm. (unlicensed) See above Treatment should be supervised by a specialist. Migraine prophylaxis (unlicensed), sprinkle capsules MR tablets, EC tablets, solution Treatment should be supervised by a specialist. Avoid abrupt withdrawal. CSM: Topiramate has been associated with acute myopia with secondary angle-closure glaucoma. Displacement of the lens and iris has also been reported. Seek specialist opthalmalogical advice. Treatment should be supervised by a specialist. CSM: inform patients how to recognise symptoms of blood, hepatic or pancreatitis effects and to seek medical attention. M/R preparations Different preparations may vary in bioavailability; to avoid reduced effect or excessive side effects, it may be prudent to avoid changing the formulation. (The use of M/R tablets significantly lessens the incidence of dose-related side effects).
15 Back References: Joint Formulary Committee. British National Formulary. 54 th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain Schnitzer TJ. Non-NSAID pharmacologic treatment options for the management of chronic. Am J Med. 1998; 105(Suppl 1B): 45S-52S. Ivon Stockley. Stockley's Drug Interactions. Pharmaceutical Press. Available from: Accessed on 30 th January Quang-Cantagrel et al. Regional Anaesthesia and Pain Medicine. Opioid Rotation in Chronic NonCancer Pain. Anesth. Anal.G. 2000;90:933 7 Summary of Product Characteristics. Versatis, Butrans, Transtec, Durogesic, Oxycontin, Oxynorm, MST Continus. Available from: accessed 30th January Twycross R, Wilcock A. PCF Palliative Care Formulary online. Available from: Accessed 30 th January Clinical Knowledge Summaries. NSAIDs. SCHIN Ltd. Centre for Health Informatics at Newcastle. Available from: Accessed 30 th January MHRA. NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks. Drug Safety Update. Volume 1, Issue 5 December 2007 Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: (9549): National Institute for Clinical Excellence. Osteoarthritis: the care and management of osteoarthritis in adults. Clinical Guidance 59. February Available from: Accessed 17/03/08 Armstrong A, Bishop S, Radhamanohar M. Medication and Risk of Falls in the Older Person. Approved: March pdf Updated 16 th September Ameet Gordhan
Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationBerkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationAnalgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-
Page 1 of 8 Analgesia The World Health Organisation (WHO, 1990) has devised a model to assist health care professionals in the management of cancer pain. The recommendations include managing pain, by the
More informationGuidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).
Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex CCG Guidelines for the
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationBJF Acute Pain Team Formulary Group
Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution
More information21 st June BDS BASHD Therapeutics Pain and Analgesia. BASHD Therapeutics Analgesics and Pain Management. Links to other BASHD content
Volume of Prescribing by Dentists 2011 ( a reminder) BASHD Therapeutics Analgesics and Pain Management Analgesics account for 1 in 80 dental prescriptions made A lot more analgesics will be suggested for
More informationtablet/capsule Paracetamol 500mg
Formulary Item Restrictions and/or Advice Non-opioid analgesics + compound analgesic preparations Aspirin 75mg dispersible Aspirin 300mg dispersible Aspirin 300mg Aspirin 75mg EC Paracetamol 500mg / Paracetamol
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationAnalgesia in patients with impaired renal function Formulary Guidance
Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function
More informationGateshead Pain Guidelines for Chronic Conditions
Gateshead Pain Guidelines for Chronic Conditions Effective Date: 13.2.2013 Review Date: 13.2.2015 Gateshead Pain Guidelines: Contents PAIN GUIDELINES Chronic Non-Malignant Pain 5 Musculoskeletal Pain 6
More informationEnhanced Community Palliative Support Services. Lynne Ghasemi St Luke s Hospice
Enhanced Community Palliative Support Services Lynne Ghasemi St Luke s Hospice Learning Outcomes Define the different types of pain Describe the process of pain assessment Discuss pharmacological management
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationYour A-Z of Pain Relief A guide to pain relief medicines. We care, we discover, we teach
Your A-Z of Pain Relief A guide to pain relief medicines We care, we discover, we teach Which pain medicines are you taking? Abstral (see Fentanyl Instant Tablets) Amitriptyline 5 Brufen (see Ibuprofen)
More information5 MUSCULOSKELETAL SYSTEM
5 MUSCULOSKELETAL SYSTEM 5.01 NON-STEROIDAL ANTIILAMMATORY DRUGS (NSAIDS) *Acetylsalicylic Acid (Aspirin) Tab Soluble 300mg Diclofenac Sodium Tab 25mg, Supp 25mg, 50mg & 100mg (Voltaren) 300-900mg every
More informationHow do we treat migraine? New SIGN Guidelines
How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood
More informationPain management in palliative care. Dr. Stepanie Lippett and Sister Karen Davies-Linihan
Pain management in palliative care Dr. Stepanie Lippett and Sister Karen Davies-Linihan contents Concept of total pain Steps in pain management Recognising neuropathic pain WHO analgesic ladder Common
More informationGG&C Chronic Non Malignant Pain Opioid Prescribing Guideline
GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline Background Persistent pain is common, affecting around five million people in the UK. For many sufferers, pain can be frustrating and disabling,
More informationOpioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.
Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationQ&A: Opioid Prescribing for Chronic Non-Malignant Pain
NHS Hastings and Rother Clinical Commissioning Group Chair Dr David Warden Chief Officer Amanda Philpott NHS Eastbourne, Hailsham and Seaford Clinical Commissioning Group Chair Dr Martin Writer Chief Officer
More informationPain Management for Adult sickle cell disease patients: Information for patients, relatives and carers
Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers Why you should read this leaflet This leaflet will give you the information necessary to manage your
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationSwitching Tramacet to paracetamol alone or paracetamol and codeine
Bulletin 62 February 2014 Community Interest Company Switching Tramacet to paracetamol alone or paracetamol and codeine This is one of a number of bulletins providing further information on medicines contained
More informationMedication For Migraine Chart: Table 1: Acute Treatment when the attack begins
Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Page a Analgesics (painkillers) Non-steroidal antiinflammatory drugs (NSAIDs) Prescription required Brand Name Formulation
More informationCOMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS
ACUTE THEAPIES TIPTANS TICYCLIC ANTIDEPESSANTS When starting acute treatment, healthcare professionals should warn patients about the risk of developing medication-overuse headache. ASPIIN Aspirin (900
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationDoncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary
Doncaster & Bassetlaw Cancer Locality Palliative Core Formulary Approved by Doncaster & Bassetlaw Hospitals NHS Foundation Trust Drugs and Therapeutics Committee. DJ14/2155 Oct 2014 Review date: Oct 2017
More informationChildren Enteric coated tablet : 1-3 mg/kg per day in divided doses.
Ultrafen Tablet/SR Tablet/Suppository/Gel Description Ultrafen is a preparation of Diclofenac is a non-steroidal antiinflammatory agent with marked analgesic, anti-inflammatory and antipyretic properties.
More informationUnderstanding your take home medications from the surgical ward. Information for Patients
Understanding your take home medications from the surgical ward Information for Patients i Information for Patients Please read this leaflet before taking the medications that have been prescribed for
More informationTreatments for migraine
Treatments for migraine Information for patients and carers Department of Neurology Aberdeen Royal Infirmary Contents Page About this leaflet Abortive medication for migraine Painkillers Antisickness medication
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationpatient group direction
NAPROXEN v01 1/10 NAPROXEN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationOpioid Conversion Guidelines
Opioid Conversion Guidelines March 2015 Gippsland Region Palliative Care Consortium Clinical Practice Group Title Keywords Ratified Opioid, Conversion, Drug, Therapy, Palliative, Guideline, Palliative,
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More informationAdult Opioid Prescribing Guidelines for Acute or Persistent Pain
Adult Opioid Prescribing Guidelines for Acute or Persistent Pain Author: Sponsor/Executive: Responsible committee: Consultation & Approval: (Committee/Groups which signed off the policy, including date)
More informationPain. Christine Illingworth. Community Nurse St Luke s Hospice 17/5/17
Pain Christine Illingworth Community Nurse St Luke s Hospice 17/5/17 What is pain? Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage Pain is whatever
More informationNHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery
Acute Sector NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery Co-ordinators: Dr Karen Cranfield, Consultant Anaesthetist, Lead Acute Pain Sector
More informationEnd of life prescribing guidance
End of life prescribing guidance Introduction This guidance has been prepared to ASSIST IN DECISION MAKING for the prescribing and monitoring of medicines useful in the management of symptoms commonly
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationManagement of headache
Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,
More informationMedicines to treat pain in adults. Information for patients and carers
Medicines to treat pain in adults Information for patients and carers It is common to feel some pain after having an operation (surgery), trauma or an infection. Controlling pain is an important part of
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute pain usually responds to medication and should settle in less than three months. Inadequate pain relief may lead to other
More informationPain Management Documents
Pain Management Documents Prescriber and Patient Resources Non-cancer Pain Guidance Neuropathic Pain Guidance Stopping or Switching low strength Buprenorphine Patches Red and Yellow Flags Medicines Management
More informationKnock Out Opioid Abuse in New Jersey:
Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids
More informationGuidelines for the Pharmacological Management of Chronic Pain in Primary Care. December 2012
Guidelines for the Pharmacological Management of Chronic Pain in Primary Care December 2012 NHS Portsmouth CCG Fareham and Gosport CCG South Eastern Hampshire CCG 1 Guidelines for the Pharmacological Management
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationPRIMARY MANAGEMENT OF DRUG PRESCRIBING IN NON-MALIGNANT PAIN
NORTH OF TYNE GUIDELINES FOR: PRIMARY MANAGEMENT OF DRUG PRESCRIBING IN NON-MALIGNANT PAIN (EXCLUDING DETAILED RECOMMENDATIONS FOR LONG TERM STRONG OPIATES) February 2015 (minor update April 2017) 1 CONTENTS
More informationIMMEDIATE DICLOFENAC NEW CONTRAINDICATIONS AND WARNINGS AFTER A EUROPE-WIDE REVIEW OF CARDIOVASCULAR SAFETY
Finance, EHealth and Pharmaceuticals Directorate Pharmacy and Medicines Division T: 0131-244 2528 E: irene.fazakerley@scotland.gsi.gov.uk 1. Medical Directors 2. Directors of Public Health 3. Directors
More informationSCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults
SCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults BACKGROUND The justification for developing these guidelines lies
More informationNHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults. Consultation Group: See Page 5
NHS...... Grampian Acute Sector NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults Co-ordinators: Consultant Anaesthetist, Lead Acute Pain
More informationClinical Guideline. Guidelines for the use of opioid analgesics in the management of acute pain in adults
Clinical Guideline Guidelines for the use of opioid analgesics in the management of acute pain in adults Document detail Document location West Kent and MTW Formulary Version 1.0 Effective from July 2017
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationPrescribing drugs of dependence in general practice, Part C
HO O Prescribing drugs of dependence in general practice, Part C Key recommendations and practice points for management of pain with opioid therapy H H HO N CH3 Acute pain Acute pain is an unpleasant sensory
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationTHE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT
1 THE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT Jaegtvolden 4-5 June 2012 14. 12. 2012 2 1 3 WHO ANALGESIC LADDER (1996) NSAID +/- Adjuvant STEP II OPIODS Opids for mild to moderate
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More informationPAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationTreating the symptoms of kidney failure
Treating the symptoms of kidney failure Information for patients, relatives and carers Renal Department The York Hospital and Scarborough Hospital Tel: 01904 725370 For more information, please contact:
More information10 Musculoskeletal and Joint Diseases
10 Musculoskeletal and Joint Diseases To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and British Society of Rheumatology guidelines and guidance
More informationPRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation
PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY This audit has been designed to ensure that patients
More informationSHARED CARE AGREEMENT: MELATONIN (CHILDREN)
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate
More informationMMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life
MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR:
M0BCore Safety Profile Active substance: Zolmitriptan Pharmaceutical form(s)/strength: ordispersible tablet P-RMS: SE/H/PSUR/0022/002 Date of FAR: 15.03.2014 4.3 Contraindications Zolmitriptan is contraindicated
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationPersistent Pain Resources. Educational Slide Set
Persistent Pain Resources Educational Slide Set October 216 This document has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory Group (AWPAG)
More informationPALLIATIVE CARE PRESCRIBING
PALLIATIVE CARE PRESCRIBING LANCASHIRE AND SOUTH CUMBRIA SPECIALIST PALLIATIVE CARE SERVICES 2010 Refer to electronic verson site for latest information. Review Date September 2011 NAVIGATIONAL INSTRUCTIONS
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationINFORMATION FOR PATIENTS. Let s Manage Pain
INFORMATION FOR PATIENTS Let s Manage Pain 1 About this booklet Persistent pain, also called chronic pain, is pain which continues for longer than expected. Pain can affect all areas of your life. People
More informationSupportive Care. End of Life Phase
Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationGUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE
GUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE GENERAL PRINCIPLES Methadone may be used as a strong opioid alternative when severe cancer-related pain responds poorly to other opioids, or
More informationGeneral Palliative Care Guidelines for the Management of Pain at the End of Life in Adult Patients
General Palliative Care Guidelines for the Management of Pain at the End of Life in Adult Patients February 2011 Contents Introduction 3 Understanding Pain 5 Principles of Pain Management 8 Assessment
More informationNeuropathic pain (pain due to nerve damage)
Neuropathic pain (pain due to nerve damage) Clinical Guideline Pain can be nociceptive, neuropathic or mixed. The neuropathic component of pain generally responds poorly to conventional analgesics. Consider
More informationOxycodone use still increasing
Oxycodone use still increasing 14 BPJ Issue 36 In BPJ 24 (Nov, 2009) we reported that oxycodone use in New Zealand had been steadily rising. Latest pharmaceutical dispensing data suggest that oxycodone
More informationPAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationA PATIENT GUIDE FOR MANAGING PAIN
A PATIENT GUIDE FOR MANAGING PAIN PAIN MANAGEMENT Knowing the Facts Pain can be controlled. Pain is common after surgery and with many types of illnesses. Most patients with acute and chronic pain can
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationManagement options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM
Management options for Migraine Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Assessment The Migraine Disability Assessment Score MIDAS Complete loss of work Partial loss of work Off
More informationNI Formulary: Chapter 4 Central Nervous system
Hypnotics Anxiolytics Acute state Non drug treatment Temazepam tablets 10mg, 20mg; oral solution 10mg/5ml or Zolpidem tablets 5mg, 10mg or Zopiclone 3.75mg, 7.5mg Non drug treatment Diazepam tablets 2mg,
More informationSIGN on the pharmacological management of migraine
GUIDELINES SIGN on the pharmacological management of migraine STEVE CHAPLIN In February 2018, the Scottish Intercollegiate Guidelines Network (SIGN) published a new guideline on the pharmacological management
More informationLong Term Care Formulary HCD - 08
1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally
More informationPALLIATIVE CARE PRESCRIBING
PALLIATIVE CARE PRESCRIBING LANCASHIRE AND SOUTH CUMBRIA SPECIALIST PALLIATIVE CARE SERVICES 2012 Refer to electronic verson at www.cancerlancashire.org.uk for latest information. Review Date January 2014
More informationDubai Standards of Care (Migraine)
Dubai Standards of Care 2018 (Migraine) Preface Migraine is one of the most common problem dealt with in daily practice. In Dubai, the management of migraine is done through various different strategies.
More informationMIGRAINE A MYSTERY HEADACHE
MIGRAINE A MYSTERY HEADACHE The migraine is a chronic neurological disease that is characterized by moderate to severe episodes of headache that is mostly associated with other central nervous system (CNS)
More informationWest Midlands Palliative Care Physicians. Palliative care. Guidelines for the use of drugs in symptom control
West Midlands Palliative Care Physicians Palliative care Guidelines for the use of drugs in symptom control Revised Jan 2012 1 5th Edition, 2012 Guidelines for the use of drugs in symptom control These
More informationNew Medicines Committee Briefing November 2011 Abstral (sublingual fentanyl citrate tablet) for the management of breakthrough cancer pain
New Medicines Committee Briefing November 2011 Abstral (sublingual fentanyl citrate tablet) for the management of breakthrough cancer pain Abstral is to be reviewed for use within: Primary Care Secondary
More informationIn our patients the cause of seizures can be broadly divided into structural and systemic causes.
Guidelines for the management of Seizures Amalgamation and update of previous policies 7 (Seizure guidelines, ND, 2015) and 9 (Status epilepticus, KJ, 2011) Seizures can occur in up to 15% of the Palliative
More informationPrimary care review of Tramadol Prescribing
Primary care review of Tramadol Prescribing Aim of the Audit To ensure the prescribing of tramadol is safe, appropriate and regularly reviewed, in line with local chronic pain guidelines 1 Background Tramadol
More informationGENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY
GENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY First issued by/date Issue Version Purpose of Issue/Description of Change Planned Review Date August 2018 1.0 Promoting generic prescribing whenever
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More information